Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Fu · SciRah

Researcher profile · Semantic Scholar

S. Fu

Share profile

S. Fu — researcher profile on SciRah

h-index: 61
Works: 508
Citations: 13K

Most-cited papers

Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials
T. Yap, N. Daver, Mikhila Mahendra, Ji-Xiang Zhang +45 more
2023Nature Medicine359 citations Open access
Semantic Scholar
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
J. Harding, V. Moreno, Y. Bang, M. Hong +15 more
2021Clinical Cancer Research127 citations Open access
Semantic Scholar
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification
S. Fu, S. Yao, Yuan Yuan, R. Previs +16 more
2022Journal of Clinical Oncology73 citations Open access
Semantic Scholar
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers.
M. Gouda, Helen J. Huang, S. Piha-Paul, S. G. Call +11 more
2022JCO Precision Oncology47 citations Open access
Semantic Scholar
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers
E. Dumbrava, S. G. Call, H.-J. Huang, A. Stuckett +17 more
2021ESMO Open42 citations Open access
Semantic Scholar
A Phase I Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
A. Hegde, P. Jayaprakash, C. Couillault, S. Piha-Paul +21 more
2021Clinical Cancer Research42 citations Open access
Semantic Scholar
Associations between the gut microbiome and fatigue in cancer patients
J. Hajjar, T. Mendoza, Liangliang Zhang, S. Fu +11 more
2021Scientific Reports41 citations Open access
Semantic Scholar
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
S. Fu, B. Corr, K. Culm-Merdek, Colleen M. Mockbee +8 more
2022Journal of Clinical Oncology38 citations Open access
Semantic Scholar
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
S. Yao, F. Janku, V. Subbiah, J. Stewart +11 more
2021British Journal of Cancer37 citations Open access
Semantic Scholar
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
T. Bauer, K. Moore, J. Rader, F. Simpkins +14 more
2023Targeted oncology35 citations Open access
Semantic Scholar
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
V. Subbiah, Niamh Coleman, S. Piha-Paul, A. Tsimberidou +14 more
2023Cancer Research Communications30 citations Open access
Semantic Scholar
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
T. DiPeri, K. Evans, M. G. Raso, Ming Zhao +12 more
2023Clinical Cancer Research25 citations Open access
Semantic Scholar
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
A. Tsimberidou, D. Hong, S. Fu, D. Karp +17 more
2021npj Precision Oncology25 citations Open access
Semantic Scholar
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
B. Nelson, J. Roszik, F. Janku, David S. Hong +12 more
2023npj Precision Oncology22 citations Open access
Semantic Scholar
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
S. Yao, F. Meric-Bernstam, D. Hong, F. Janku +14 more
2022Scientific Reports22 citations Open access
Semantic Scholar
Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
S. Yao, F. Janku, K. Koenig, A. Tsimberidou +7 more
2021Cancer Medicine22 citations Open access
Semantic Scholar
Abstract CT107: Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors
B. Nelson, F. Janku, S. Fu, E. Dumbrava +14 more
2023Cancer Research18 citations
Semantic Scholar
Phase I/II trial of avelumab combined with utomilumab (4–1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies
A. Knisely, Jibran Ahmed, B. Stephen, S. Piha-Paul +14 more
2023Cancer18 citations
Semantic Scholar
295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas
N. Lakhani, M. Orloff, S. Fu, Ying Liu +6 more
202016 citations Open access
Semantic Scholar
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
B. Stephen, J. Hajjar, S. Sarda, D. Duose +15 more
2023Journal for ImmunoTherapy of Cancer15 citations Open access
Semantic Scholar
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Roberto Carmagnani Pestana, J. Moyers, J. Roszik, S. Sen +30 more
2023Clinical Cancer Research15 citations Open access
Semantic Scholar
481 Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanced solid tumors
G. Falchook, H. Gan, S. Fu, M. McKean +14 more
2021Journal for ImmunoTherapy of Cancer15 citations Open access
Semantic Scholar
First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.
T. Yap, E. Dumbrava, Jordi Rodon Ahnert, D. Hong +16 more
202115 citations
Semantic Scholar
A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies
S. Fu, D. Piccioni, Hong-Tao Liu, R. Lukas +10 more
2021Scientific Reports13 citations Open access
Semantic Scholar
Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab
Sang T. Kim, J. Tayar, S. Fu, Danxia Ke +4 more
2021Journal for ImmunoTherapy of Cancer11 citations Open access
Semantic Scholar
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
T. Cascone, R. Sacks, I. Subbiah, N. Drobnitzky +16 more
2021ESMO Open11 citations Open access
Semantic Scholar
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer
S. Westin, S. Fu, A. Tsimberidou, S. Piha-Paul +17 more
2022Gynecologic Oncology10 citations
Semantic Scholar
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
H. Vo, S. Fu, D. Hong, D. Karp +19 more
2022npj Precision Oncology9 citations Open access
Semantic Scholar
Overview of Ocular Side Effect of Selinexor.
N. Al-Zubidi, D. Gombos, D. Hong, V. Subbiah +7 more
2021The Oncologist9 citations Open access
Semantic Scholar
Abstract 974: Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification
S. Fu, S. Yao, Yuan Yuan, R. Previs +17 more
2021Experimental and Molecular Therapeutics9 citations
Semantic Scholar
SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer (LBA 9)
S. Westin, K. Kurnit, B. Fellman, Priya Bhosale +17 more
2023Gynecologic Oncology8 citations
Semantic Scholar
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors
B. Nelson, A. Tsimberidou, Xueyao Fu, S. Fu +8 more
2023The Oncologist8 citations Open access
Semantic Scholar
Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers.
B. Nelson, Clark R. Andersen, Ying Yuan, D. Hong +16 more
2022Journal of Clinical Oncology8 citations
Semantic Scholar
Abstract CT503: A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies
S. Fu, U. Banerji, Philippe Bédard, A. Ferrandiz +12 more
2022Cancer Research8 citations
Semantic Scholar
First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers.
A. Ho, M. Posner, J. Niu, S. Fu +16 more
20218 citations
Semantic Scholar
Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience
B. Nelson, C. Ejezie, B. Stephen, M. Nardo +10 more
2022Journal of Hematology7 citations Open access
Semantic Scholar
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)
J. Moyers, Roberto Carmagnani Pestana, J. Roszik, D. Hong +19 more
2022Clinical Cancer Research7 citations Open access
Semantic Scholar
Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab.
S. Fu, W. Harb, S. Patel, Charles Lu +10 more
20217 citations
Semantic Scholar
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
K. Thein, S. Piha-Paul, A. Tsimberidou, D. Karp +14 more
2021Experimental Hematology & Oncology7 citations Open access
Semantic Scholar
Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.
S. Piha-Paul, Bing-He Xu, F. Janku, E. Dumbrava +15 more
20217 citations
Semantic Scholar
Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens.
Ming-Xuan Xu, C. Tapia, J. Hajjar, Sharjeel H. Sabir +25 more
2021Journal of Immunotherapy and Precision Oncology7 citations Open access
Semantic Scholar
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
O. Alhalabi, R. Groisberg, R. Zinner, A. Hahn +17 more
2023npj Precision Oncology6 citations Open access
Semantic Scholar
First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.
G. Falchook, Yan Liang, R. Harvey, S. Fu +16 more
2023Journal of Clinical Oncology6 citations Open access
Semantic Scholar
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
S. Piha-Paul, C. Tseng, H. Tran, Meng Gao +12 more
2023Cancer Chemotherapy and Pharmacology6 citations Open access
Semantic Scholar
Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
E. Pisick, M. Rothe, P. Mangat, Liz Garrett-Mayer +13 more
20216 citations
Semantic Scholar
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
K. Thein, D. Karp, A. Tsimberidou, J. Gong +14 more
2021Investigational new drugs6 citations Open access
Semantic Scholar
797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)
N. Khushalani, A. Brohl, J. Markowitz, L. Bazhenova +8 more
20206 citations Open access
Semantic Scholar
Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center.
T. M. Davidson, Hung Le, E. Campbell, Cherri A. Ozenne +11 more
2023Journal of Clinical Oncology5 citations
Semantic Scholar
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
S. Piha-Paul, E. Dumbrava, B. Nair, W. Xiong +13 more
2021OncoTargets and Therapy5 citations Open access
Semantic Scholar
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study
R. Dev, L. Zhong, A. Zarifa, A. Albittar +12 more
2021Investigational new drugs5 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Piha-Paul×34
Invite
S. Piha-Paul — researcher profile on SciRah
F. Meric-Bernstam×30
Invite
F. Meric-Bernstam — researcher profile on SciRah
D. Karp×27
Invite
D. Karp — researcher profile on SciRah
A. Naing×27
Invite
A. Naing — researcher profile on SciRah

×27

Invite

A. Tsimberidou — researcher profile on SciRah

Invite

V. Subbiah — researcher profile on SciRah

Invite

D. Hong — researcher profile on SciRah

Invite

T. Yap — researcher profile on SciRah

Invite

F. Janku — researcher profile on SciRah

Invite

S. Pant — researcher profile on SciRah

Invite

J. Rodón — researcher profile on SciRah

Invite

E. Dumbrava — researcher profile on SciRah